



200.1133CON2

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner: James Henry Alstrum Acevedo Art Unit: 1615

Re: Application of: Benjamin OSHLACK, et al.

Serial No.: 10/701,041

Filed: November 4, 2003

For: **TAMPER-RESISTANT ORAL OPIOID  
AGONIST FORMULATIONS**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

July 10, 2007

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (1 page) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. 1.98(a)(2), a copy of each cited document is enclosed. If it is determined that a copy of any of the cited documents is missing, the Examiner is requested to contact the undersigned so that the missing copy may be forwarded.


It is respectfully requested that the documents listed on the accompanying Form PTO-1449 (1 page) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97 (b), before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. In the event any additional fee is due in connection with the filing of this Information

Disclosure Statement, the Commissioner is hereby authorized to charge said deficiency to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:   
Robert J. Paradiso  
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14th Floor  
New York, New York 10018  
(212) 736-1940

COMMISSIONER FOR PATENTS  
P.O.Box 1450  
Alexandria, VA 22313-1450



In re application of: Benjamin Oshlack  
Serial No.: 10/701,041


Filed: November 4, 2003

For: TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Sir:


Transmitted herewith is a **Supplemental Information Disclosure Statement (2 pages)** in the above-identified application.

- ☐ Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.
- ☐ Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.
- ☐ No fee for additional claims is required.
- ☐ A filing fee for additional claims calculated as shown below, is required:
- ☒ Also transmitted herewith are:
- ☐ Petition
- ☒ Other: **Form PTO 1449 (1 page) with copies of the cited references.**
- ☐ Check(s) in the amount of **\$00.00** is/are attached to cover:
- ☐ Filing fee for additional claims under 37 C.F.R. 1.16
- ☐ Petition fee for extension under 37 C.F.R. 1.136
- ☐ Other:
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.
- ☐ Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.
- ☒ Any patent application processing fees under 37 C.F.R. 1.17.
- ☒ Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

  
Robert J. Paradiso, Reg. No. 41, 240  
DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
Tel: (212) 736-1940  
Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service with sufficient postage as "first class mail" in an envelope addressed to Mail Stop: Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 10, 2007.

BY:

  
Oleg Ioselevich

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON2		SERIAL NO.: 10/701,041	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use additional sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: November 4, 2003		GROUP: 1615	

U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
AA									
AB									
AC									
AD									
AE									
AF									
AG									
AH									

FOREIGN PATENT DOCUMENTS									
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
					YES	NO			
AI									

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
AJ	Philip D. Kanof et al., "Levels of Opioid Physical Dependence in Heroin Addicts," Drug and Alcohol Dependence, 27 (1991) 253-262.
AK	J.E. Peachey et al., "Assessment of Opioid Dependence with Naloxone," British Journal of Addiction (1988) 83(2), 193-201
AL	John G. Nutt et al., "Methadone-naloxone Mixtures for Use in Methadone Maintenance Programs," Clinical Pharmacology and Therapeutics, Vol. 15, Number 2, pp. 156-166, received for publication June 11, 1973
AM	Richard I. H. Wang et al., "Rating the Presence and Severity of Opiate Dependence," Clinical Pharmacology and Therapeutics, Volume 16, Number 4, pp. 653-657; received for publication January 21, 1974
AN	Richard B. Resnick et al., "Naloxone Precipitated Withdrawal: A Method For Rapid Induction Onto Naltrexone," Clinical Pharmacology and Therapeutics, Volume 21, Number 4, pp. 409-413; received for publication November 16, 1976
AO	Barbara A. Judson et al., "The Naloxone Test Opiate Dependence," Clin. Pharmacol. Ther., Vol. 27, Number 4, pp. 492-501, received for publication September 15, 1979
AP	Philip D. Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects," The Journal of Pharmacology and Experimental Therapeutics, Vol. 260, No. 1, pp. 355-363, 1992
AQ	Richard L. Wiesen et al., "The Safety and Value of Naloxone as a Therapeutic Aid," Drug and Alcohol Dependence, 2 (1977) pp. 123-130
AR	
AS	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.